Ma Yiming, Liu Xiangming, Long Yingjiao, Chen Yan
Department of Pulmonary and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, China.
Front Bioeng Biotechnol. 2022 Feb 25;10:845042. doi: 10.3389/fbioe.2022.845042. eCollection 2022.
Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) are able to carry genetic and protein goods to mediate the interaction between MSCs and target cells. Recently, more and more researches have focused on the therapeutic role of MSC-EVs in chronic respiratory diseases. In this review, we summarize the cumulative strategies and mechanisms of MSC-EVs in treating chronic respiratory diseases. This review suggests that MSC-EVs may serve as a novel cell-free-based therapy for chronic respiratory diseases, including COPD, asthma, pulmonary fibrosis, and pulmonary arterial hypertension. In current studies of chronic respiratory diseases, umbilical cord and bone marrow are main sources of MSC-EVs, while adipose tissue, lung, and induced pluripotent stem cells are also applied. Isolation methods of MSC-EVs in treating chronic respiratory diseases involve ultracentrifugation, exosome extraction kits and anion-exchange chromatography. Intratracheal delivery and intravenous administration are the most widely used routes of MSC-EVs. MSC-EVs are able to transfer microRNAs and protein to target cells and further magnify the therapeutic effects.
间充质干细胞衍生的细胞外囊泡（MSC-EVs）能够携带遗传物质和蛋白质产物，介导间充质干细胞与靶细胞之间的相互作用。近年来，越来越多的研究聚焦于MSC-EVs在慢性呼吸道疾病中的治疗作用。在本综述中，我们总结了MSC-EVs治疗慢性呼吸道疾病的累积策略和机制。本综述表明，MSC-EVs可能成为一种用于慢性呼吸道疾病的新型无细胞疗法，包括慢性阻塞性肺疾病（COPD）、哮喘、肺纤维化和肺动脉高压。在目前关于慢性呼吸道疾病的研究中，脐带和骨髓是MSC-EVs的主要来源，脂肪组织、肺和诱导多能干细胞也有应用。治疗慢性呼吸道疾病时，MSC-EVs的分离方法包括超速离心、外泌体提取试剂盒和阴离子交换色谱法。气管内给药和静脉内给药是MSC-EVs最广泛使用的给药途径。MSC-EVs能够将微小RNA和蛋白质转移至靶细胞，并进一步放大治疗效果。
